Persistence of Infectious Canine Distemper Virus in Murine Xenotransplants of Canine Histiocytic Sarcoma Cells after Intratumoral Application
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158297 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mara Sophie Lombardo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany. Hauptthemen laut MEDLINE: Distemper Virus, Canine, Histiocytic Sarcoma, Oncolytic Virotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Access Publication Fund of the University of Veterinary Medicine Hannover, Foundation, Brigitte und Prof. Dr. Reiner Müller-Peddinghaus Foundation.
Abstract (Originalsprache)
Oncolytic viruses and morbilliviruses in particular, represent an interesting therapeutic approach for tumors with a poor prognosis and frequent resistance to conventional therapies. Canine histiocytic sarcomas (HS) exemplify such a neoplasm in need for new curative approaches. Previous investigations demonstrated a limited success of an acute intratumoral application of canine distemper virus (CDV) on xenotransplanted canine histiocytic sarcoma cells (DH82 cells), while persistently CDV-infected DH82 cell transplants exhibited a complete spontaneous regression. Therefore, the present study focuses on an intratumoral application of persistently CDV vaccine strain Onderstepoort-infected DH82 (DH82 Ond p.i.) cells into non-infected subcutaneous DH82 cell transplants in a murine model. DH82 cell transplants that received 10 applications, two days apart, showed a transient growth retardation as well as larger areas of intratumoral necrosis, lower mitotic rates, and a decreased intratumoral vascularization compared to controls. Viral mRNA was detected in all neoplasms following application of DH82 Ond p.i. cells until 66 days after the last injection. Furthermore, infectious virus was present until 62 days after the last injection. Although complete regression was not achieved, the present application regimen provides promising results as a basis for further treatments, particularly with genetically modified viruses, to enhance the observed effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
- Pathology Unit, Veterinary Medicine Department, University of Parma, 43126 Parma, Italy.
- Institute for Biometry, Epidemiology and Information Processing, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
ORCID-Profile: Federico Armando, Wolfgang Baumgärtner, Christina Puff
Förderung
- Open Access Publication Fund of the University of Veterinary Medicine Hannover, Foundation
- Brigitte und Prof. Dr. Reiner Müller-Peddinghaus Foundation
Zitieren
APA
Lombardo, M. S., Armando, F., Marek, K., Rohn, K., Baumgärtner, W., & Puff, C. (2024). Persistence of Infectious Canine Distemper Virus in Murine Xenotransplants of Canine Histiocytic Sarcoma Cells after Intratumoral Application. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158297
Vancouver
Lombardo MS, Armando F, Marek K, Rohn K, Baumgärtner W, Puff C. Persistence of Infectious Canine Distemper Virus in Murine Xenotransplants of Canine Histiocytic Sarcoma Cells after Intratumoral Application. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158297
BibTeX
@article{Lombardo2024,
author = {Lombardo, Mara Sophie and Armando, Federico and Marek, Katarzyna and Rohn, Karl and Baumgärtner, Wolfgang and Puff, Christina},
title = {Persistence of Infectious Canine Distemper Virus in Murine Xenotransplants of Canine Histiocytic Sarcoma Cells after Intratumoral Application},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158297}
}
EUVIMED